Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $5.06
Previous CloseN/A
Volume1.63M
Average Volume (3M)10.55M
Market Cap
$949.01M
Enterprise Value$999.78M
Total Cash (Recent Filing)$396.88M
Total Debt (Recent Filing)$121.78M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 07, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding636,917,800
10 Day Avg. Volume8,676,304
30 Day Avg. Volume10,551,870
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)3.75
Price to Sales (P/S)0.00
P/FCF Ratio-4.71
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue4.46
Enterprise Value/Gross Profit8.79
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$4.10Price Target Upside175.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Geron News
PremiumCompany Announcements
Geron Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Geron Corporation’s Q1 2025 Financial HighlightsPremiumCompany Announcements
Geron Corporation’s Earnings Call: Mixed Sentiments and Strategic Moves
Bulls Say, Bears Say
Bulls Say
Patient DemandManagement is hopeful it will deliver based on early signs of progress including a ~10% demand increase from March - April.
Sales Force ExpansionManagement provided details on launch strategies to drive new patient starts, including a 20% expansion to the field force.
Sales TrajectoryA positive trend is starting to emerge in the weekly sales data, which is viewed as encouraging.
Bears Say
Inventory DrawdownRevenues were down due to an inventory drawdown caused by overstocking in the previous quarter.
Inventory DynamicsRytelo net product revenues were below consensus and down due to inventory dynamics against flat demand.
Quarterly Sales DeclineGeron reported Q1 Rytelo net sales of $39MM (-17% Q/Q), which is below our estimate of $49MM and consensus of $48MM.
Ownership Overview
0.10% Insiders
11.74% Mutual Funds
35.07% Other Institutional Investors
39.12% Public Companies and Individual Investors
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.17 and its highest was $5.06 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $949.01M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Aug 07, 2025 which is in 39 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on May 07, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.036 by $0.006.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 636,917,800 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.036. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.10 (175.17% Upside)
$4.10 (175.17% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 25.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.44%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Company Deck
GERN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed sentiment. While there are encouraging signs of growth and strategic investments to bolster RYTELO's market presence, the decline in Q1 revenues, challenges in physician adoption, and reliance on third-party support in the EU present significant concerns. The ongoing executive transition adds to the uncertainty.Read More>GERN Stock 12 Month Forecast
Average Price Target
$4.10
▲(175.17%Upside)
Technical Analysis
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Spyre Therapeutics
―
Pulse Biosciences
―
Enliven Therapeutics
―